24.00
Schlusskurs vom Vortag:
$24.72
Offen:
$24.74
24-Stunden-Volumen:
70,647
Relative Volume:
1.00
Marktkapitalisierung:
$802.75M
Einnahmen:
Nettoeinkommen (Verlust:
$-43.60M
KGV:
-4.5374
EPS:
-5.2894
Netto-Cashflow:
1W Leistung:
-3.69%
1M Leistung:
-16.08%
6M Leistung:
-4.12%
1J Leistung:
+0.00%
Spyglass Pharma Inc Stock (SGP) Company Profile
Firmenname
Spyglass Pharma Inc
Sektor
Branche
Telefon
949-284-6904
Adresse
27081 ALISO CREEK ROAD, ALISO VIEJO
Compare SGP vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
SGP
Spyglass Pharma Inc
|
24.00 | 802.75M | 0 | -43.60M | 0 | -5.2894 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Spyglass Pharma Inc Stock (SGP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-14 | Eingeleitet | Raymond James | Outperform |
| 2026-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-03-03 | Eingeleitet | Citigroup | Buy |
| 2026-03-03 | Eingeleitet | Jefferies | Buy |
| 2026-03-03 | Eingeleitet | Leerink Partners | Outperform |
| 2026-03-03 | Eingeleitet | Stifel | Buy |
Alle ansehen
Spyglass Pharma Inc Aktie (SGP) Neueste Nachrichten
H.C. Wainwright reiterates SpyGlass Pharma stock rating at buy By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates SpyGlass Pharma stock rating at buy - Investing.com
H.C. Wainwright reiterates SpyGlass Pharma stock rating at buy By Investing.com - Investing.com Canada
SpyGlass Pharma Acquires Advanced Vision Science, Securing Commercial IOL Supply, Accelerating Lens Portfolio Expansion - VisionMonday.com
SpyGlass Pharma Acquires Advanced Vision Science for $13 Million - Minichart
SpyGlass Pharma Acquires Advanced Vision Science, Inc. - GlobeNewswire
Spyglass Pharma (NASDAQ:SGP) Shares Down 4.5%What's Next? - MarketBeat
Spyglass Pharma, Inc. (NASDAQ:SGP) Stock Has Average Target Price of $44.00 - MarketBeat
SpyGlass Pharma (NasdaqGS:SGP) Stock Price - Simply Wall Street
Spyglass Pharma (NASDAQ:SGP) Upgraded at Wall Street Zen - MarketBeat
Spyglass Pharma (NASDAQ:SGP) Trading Down 5.3%Should You Sell? - MarketBeat
SpyGlass Pharma at Citigroup summit: glaucoma lens nears phase iii By Investing.com - Investing.com Australia
SpyGlass Pharma at Citigroup summit: glaucoma lens nears phase iii By Investing.com - Investing.com Canada
SpyGlass Pharma (SGP) Holds Near $27.55 as Traders Eye the $28.93 CeilingBreadth Thrust - dars.gov.et
SpyGlass Pharma (SGP) Holds Near $27.55 as Traders Eye the $28.93 CeilingMoney Flow Index - careplusvn.com
SpyGlass Pharma Expands to Bigger HQ in Irvine - Orange County Business Journal
SpyGlass Pharma to Participate in Upcoming Investor Conferences - GlobeNewswire
Three September conferences will include SpyGlass Pharma. Two talks will be webcast. - Stock Titan
SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space - Moomoo
SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space - PR Newswire
SpyGlass (SGP) Trading: Closes 1.00% Lower at $26.25; Traders Can Monitor the $24.94-$27.56 Range for the Current SessionContinuation Pattern Picks - vinanet.vn
SpyGlass (SGP) Earnings Reading: EPS Misses Its Estimate in the Available Record; Share Move - vinanet.vn
SpyGlass (SGP): Finishes 1.91% Lower at $26.71; Technical Setup: the Current Price Sits Inside the Supplied Technical Range in the Available RecordWyckoff Accumulation - vinanet.vn
SpyGlass (SGP): Finishes 1.91% Lower at $26.71; Technical Setup: the Current Price Sits Inside the Supplied Technical Range in the Available RecordLate Stage Breakouts - siam.in
SpyGlass (SGP) Financial Update: Profit Per Share Falls Below Its Benchmark under the Current Snapshot - vinanet.vn
SpyGlass Pharma (SGP) Slides 2.4% as Shares Test Mid-Range Support ZoneBlock Trade Flow - vinanet.vn
SpyGlass Pharma (SGP) Slides 2.4% as Shares Test Mid-Range Support ZoneMutual Fund Flow - siam.in
Spyglass Pharma (NASDAQ:SGP) Upgraded to "Moderate Buy" at Raymond James Financial - MarketBeat
Analysts Offer Insights on NA Companies: Ottobock SE & Co. KGaA (OtherOBCKF), SpyGlass Pharma (Nasdaq: SGP) and Figure Technology Solutions, Inc. Class A (FIGR) - The Globe and Mail
Analysts Offer Insights on NA Companies: Ottobock SE & Co. KGaA (OtherOBCKF), SpyGlass Pharma (Nasdaq: SGP) and Figure Technology Solutions, Inc. Class A (FIGR) - theglobeandmail.com
SpyGlass Pharma, Inc. (NASDAQ: SGP) Share Price, SGP Stock News, SGP Share Price & Updates - Kalkine
SpyGlass Pharma, Inc. (NASDAQ: SGP) Share Price, SGP Stock News, SGP Share Price & Updates - kalkine.ca
Raymond James Initiates SpyGlass Pharma(SGP.US) With Buy Rating, Announces Target Price $39 - Moomoo
Raymond James initiates SpyGlass Pharma stock coverage with outperform rating - Investing.com
Raymond James initiates SpyGlass Pharma stock coverage with outperform rating - Investing.com India
Raymond James initiates SpyGlass Pharma stock coverage with outperform rating - Investing.com Canada
Q3 EPS Estimates for Spyglass Pharma Decreased by Analyst - MarketBeat
SpyGlass Pharma Reports Q2 Financials, Provides Corporate Updates - visionmonday.com
SpyGlass Pharma Ord shs (Proposed) (SGP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Spyglass Pharma, Inc. (NASDAQ:SGP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
SpyGlass Pharma 2Q 2026: Net loss $(19.9)M, EPS $(0.59) — 10-Q Summary - TradingView
[10-Q] SpyGlass Pharma, Inc. Quarterly Earnings Report - Stock Titan
SpyGlass Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
SpyGlass Pharma reports $19.9M Q2 net loss, $234.2M cash and investments as of June 30, 2026 - TradingView
SpyGlass Pharma Q2 net loss widens on higher expenses - TradingView
SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - Yahoo Finance
SpyGlass Pharma Insiders Enjoying US$1.1m Appreciation On US$2.16m Investment - webull.com
SpyGlass Pharma (SGP) Rallies 3.08% to $24.41 as Ophthalmic Focus Draws Fresh BuyingLow Vol Factor - dars.gov.et
SpyGlass Pharma (SGP) Climbs 5.5% as Bulls Eye Resistance at $26.24Catalyst Driven Stocks - dars.gov.et
SpyGlass Pharma (SGP) Rallies 3.08% to $24.41 as Ophthalmic Focus Draws Fresh BuyingMedian Line - dars.gov.et
Finanzdaten der Spyglass Pharma Inc-Aktie (SGP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spyglass Pharma Inc-Aktie (SGP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Behbahani Ali | Director |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Florence Anthony A. Jr. | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| BASKETT FOREST | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| New Enterprise Associates 17, | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Yang Rick | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Makhzoumi Mohamad | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| SANDELL SCOTT D | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Chang Carmen | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Walker Paul Edward | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Mathers Edward T | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):